Dr. Ali Tehrani is the President, Chief Executive Officer and Co-Founder of Zymeworks, a clinical-stage biotherapeutics company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer. Under Dr. Tehrani’s leadership, Zymeworks has been recognized by BIOTECanada and LifeSciences British Columbia as Life Sciences Company of the Year, among other notable awards and achievements, and has entered into strategic partnerships with multiple global pharmaceutical companies. He is a recipient of the University of British Columbia (UBC) Faculty of Science Achievement Award for Outstanding Leadership for co-founding the Student Biotechnology Network while completing his PhD. Dr. Tehrani has served as a director on the board of LifeSciences British Columbia, and has contributed his expertise and knowledge of the global life sciences industry, as well as entrepreneurship within the tech and biotechnology sectors to the MITACS Industrial Advisory Board, BIOTECanada’s Industrial and Environmental Committee and the Student Biotechnology Network. He is presently a member of the Board of Directors of CQDM, formerly the Quebec Consortium for Drug Discovery. Dr. Tehrani holds a Doctoral (PhD) degree in Microbiology and Immunology from UBC in addition to a Master of Science and Bachelor of Science in Biochemistry from the University of Massachusetts (Amherst).